non-opioid alternative to current IV-based cataract surgery sedation protocols, which generally involve the administration of opioids,” said Dr Larry Dillaha, Chief Executive Officer of Melt.
Melt Pharmaceuticals has reported encouraging topline results from its Phase III trial of MELT-300, a non-intravenous, ...
MELT-300, a non-IV, non-opioid sedation tablet, showed positive Phase 3 results for cataract surgery, supporting FDA ...
a non-IV, non-opioid tablet for procedural sedation during cataract surgery. Based on a Special Protocol Assessment agreement reached with the U.S. Food and Drug Administration earlier this year ...
Melt Pharmaceuticals announced positive topline results of its pivotal Phase 3 study evaluating the safety and efficacy of its lead product ...